Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.
Chi Yan WongRoland LeungGin Wai KwokJosephine TsangBryan LiThomas YauJoanne Wing Yan ChiuPublished in: Postgraduate medical journal (2021)
With a median follow-up of 21.7 months, 20 patients were enrolled. One patient (5%) developed asymptomatic drop in left ventricular ejection fraction from 69% to 53%. Two patients (10%) developed grade 1 injection site reaction related to SC trastuzumab. There were no grade 2 or above AEs. All AEs were transient. No new AEs were observed. The 1-year iDFS was 90% (95% CI 0.656 to 0.974) CONCLUSIONS: Combination of SC trastuzumab and intravenous pertuzumab for HER2-positive breast cancer is a safe and well-tolerated option in adjuvant setting.
Keyphrases
- ejection fraction
- positive breast cancer
- aortic stenosis
- end stage renal disease
- epidermal growth factor receptor
- left ventricular
- newly diagnosed
- chronic kidney disease
- metastatic breast cancer
- prognostic factors
- heart failure
- peritoneal dialysis
- high dose
- clinical trial
- case report
- mitral valve
- acute coronary syndrome
- acute myocardial infarction
- brain injury
- ultrasound guided
- patient reported